1
|
Cheuk IW, Chen J, Siu M, Ho JC, Lam SS, Shin VY, Kwong A. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. Clin Transl Oncol 2021; 24:854-863. [PMID: 34859370 DOI: 10.1007/s12094-021-02731-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 11/01/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND Resveratrol, a naturally occurring polyphenolic compound, has been shown to inhibit cancer growth by targeting several cancer-related signalling pathways. In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant leukocyte population that are associated with poor prognosis in over 80% of breast cancer cases. However, little is known about the effect of resveratrol in the TME. METHODS In this study, MDA-MB-231(MB231), cisplatin resistance MDA-MB-231 (cisR), and T47D were used to examine the antitumor effect of resveratrol. The effectiveness of resveratrol, together with cisplatin as breast cancer treatment was investigated in vivo. Gene expressions of M1 (iNOS and CXCL10) and M2 (ARG1, CD163 and MRC1) markers in differentiated macrophages derived from THP-1 cells were examined to investigate the effect of resveratrol on TAM polarization in breast cancer progression. RESULTS Our results demonstrated that resveratrol significantly reduced cell proliferation and enhanced chemosensitivity in breast cancer cells by inhibiting production of IL-6 and STAT3 activation. Treatment of resveratrol increased CXCL10 (M1 marker) expression. Further, resveratrol decreased IL-6 levels in LPS-treated differentiated macrophages. The use of resveratrol with cisplatin inhibited suppressed tumor growth when compared with cisplatin alone. CONCLUSION This study revealed that resveratrol inhibited breast cancer cell proliferation by promoting M1/M2 macrophage polarization ratio and suppressing IL-6/pSTAT3 pathway.
Collapse
Affiliation(s)
- I W Cheuk
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - J Chen
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - M Siu
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - J C Ho
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - S S Lam
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - V Y Shin
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China
| | - A Kwong
- Department of Surgery, The University of Hong Kong and The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China.
- Department of Surgery, The Hong Kong Sanatorium and Hospital, Hong Kong SAR, China.
- The Hong Kong Hereditary Breast Cancer Family Registry, Room K1401, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.
| |
Collapse
|
2
|
Leung WK, Shin VY, Law WL. Detection of methylated septin 9 DNA in blood for diagnosis, prognosis, and surveillance of colorectal cancer. Hong Kong Med J 2019; 25 Suppl 9:32-34. [PMID: 31889033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Affiliation(s)
- W K Leung
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong
| | - V Y Shin
- Department of Surgery, Queen Mary Hospital, The University of Hong Kong
| | - W L Law
- Department of Surgery, Queen Mary Hospital, The University of Hong Kong
| |
Collapse
|
3
|
Kwong A, Chen J, Siu J, Chuek I, Shin V. Abstract P6-05-04: NEAT1 enhances drug sensitivity by inhibiting cancer stem-like cells in triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Accumulating evidence showed that long non-coding RNAs (lncRNAs) dysregulation is the hallmark of cancer. Nuclear paraspeckle assembly transcript 1 (NEAT1) has been reported to overexpress in many cancers, and promote cell growth and disease progression. However, the role of NEAT1 on drug sensitivity and stem-cell like property in triple-negative breast cancer is largely unknown.
Methods: LncRNA expression profile were compared between breast cancer patients and healthy individuals using lncRNA array. Large scale validation of NEAT1 expression in blood samples were performed by real-time PCR. Triple-negative breast cancer (TNBC) cells, MDA-MB-231 and its cisplatin resistance subline (MDA-MB-231/cis) were used. Stable transfection of cells with NEAT1 knockdown by shRNA, and evaluated single cell clonogenic assay, aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- and other cancer stem cell (CSC) markers. Drug sensitivity assay, flow cytometry analysis, immunofluorescence staining and xenograft model were used to assess the functional role of NEAT1.
Results: Array data showed that NEAT1 was the top upregulated lncRNAs in the plasma of breast cancer patients. Consistent with the array data, validation of larger cohort of patients and healthy individuals (n=369) also demonstrated a higher expression of NEAT1 in breast cancer patients, in particular TNBC subtype. Knockdown of NEAT1 by shRNA sensitized breast cancer cells to cisplatin and taxol treatment. Cell proliferation and colony formation abilities were reduced with S-phase cell cycle arrest in shNEAT1 cells. Flow cytometry analysis revealed an induction of apoptosis with increased cleaved caspase-3. Cells expressing shNEAT1 abrogated ALDH activity, CD44+/CD24- subpopulation and expression of CSC markers (SOX2, NANOG and OCT4). More importantly, shNEAT1 cells retarded tumor growth in xenograft mice model and reduced CSC markers.
Conclusion: Taken together, NEAT1 expression is differentially expressed in breast cancer patients, and particularly higher in patients with TNBC. These findings suggest a potent therapeutic target to improve drug sensitivity in patients with TNBC.
Citation Format: Kwong A, Chen J, Siu J, Chuek I, Shin V. NEAT1 enhances drug sensitivity by inhibiting cancer stem-like cells in triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-05-04.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - J Chen
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - J Siu
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - I Chuek
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - V Shin
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| |
Collapse
|
4
|
Kwong A, Shin V, Au CH, Ho C, Slavin T, Weitzel J, Chan TL, Ma E. Abstract P5-09-12: Germline mutation in TP53 gene in a cohort of 2,561 Chinese high-risk breast cancer patients using multigene panel testing. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-09-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Li-Fraumeni syndrome (LFS) is a rare autosomal genetic disorder with germline TP53 mutations. Patients with TP53 mutations have a higher risk of developing breast cancer than those harboring BRCA mutations. Although limited studies have shown that TP53 mutation carriers are less responsive to low dose radiation and more susceptible to induce new malignancies from radiotherapy. Moreover screening strategies allows early detection of a spectrum of cancers related to TP53 mutations. From work of BRCA mutations where over 40% novel mutations were detected in Chinese cohort, it is important to evaluate the frequency of TP53 mutation in Chinese to better understand the spectrum to guide appropriate clinical management of these high risk individuals.
Methods: TP53 gene mutation screening was performed on 2,561 high-risk breast cancer patients using multigene panel testing. The patients were accrued by Hong Kong Hereditary and High Risk Breast Cancer Program from March 2007 to May 2018. All detected pathogenic mutations were further validated by bi-directional DNA sequencing and analyzed by our in-house developed bioinformatics pipeline.
Results: Sixteen distinct pathogenic or likely pathogenic variants were identified, and 3 of them were de novo TP53 mutations (18.75%). The mean age of patients who harbored TP53 mutation was 30.44 years (range 18-44), and 50% of the tumors were bilateral breast cancer. Of sixteen different pathogenic mutations, majority of them were missense mutation (87.5%), and 2 were nonsense mutation (12.5%). Four of the sixteen TP53 mutation carriers had family history of breast cancer, while others had a family history of lung cancer (43.75%).
Conclusion: This study revealed that seven patients were found to habor TP53 mutation even when they did not meet the criteria of LFS of LFS-like phenotype, implicated the importance of using multigene panel test for probands and their relatives to offer a comprehensive surveillance programe for TP53 carriers.
Citation Format: Kwong A, Shin V, Au CH, Ho C, Slavin T, Weitzel J, Chan TL, Ma E. Germline mutation in TP53 gene in a cohort of 2,561 Chinese high-risk breast cancer patients using multigene panel testing [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-09-12.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - V Shin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - CH Au
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - C Ho
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - T Slavin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - J Weitzel
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - TL Chan
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - E Ma
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| |
Collapse
|
5
|
Kwong A, Wang J, Chen J, Siu MT, Chuek I, Shin V. Abstract P4-01-24: S100A11 is a diagnostic marker and promotes cancer progression for luminal breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-01-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: S100A11, also known as calgizzarin, is a member of S100 calcium-binding protein family and is upregulated in various cancers including lung cancer, renal cell cancer, ovarian cancer and pancreatic cancer. Many studies have shown that S100A11 is related to cancer progression. However, the function of S100A11 in breast cancer remains largely unknown. In the present study, we aim to investigate the underlying mechanism(s) of S100A11 in cancer cell proliferation, invasion, migration, and evaluate the clinical association with breast cancer.
Methods: The mRNA expression level of S100A11 in plasma samples from breast cancer patients and normal control individuals was detected with quantitative real-time PCR. Knockdown of S100A11 using small interfering RNA (siRNA) in luminal breast cancer cells (MCF-7 and T-47D) were used to study the biological function of S100A11 for the progression of breast cancer. Cell proliferation ability was analysed with MTT assay and colony formation assay. Cell invasion ability was analysed with transwell invasion assay. Cell migration ability was detected by wound healing assay. Cell cycle distribution and apoptosis were determined by flow cytometry.
Results: The mRNA expression level of S100A11 was significantly increased in the plasma samples obtained from 182 breast cancer patients compared with 115 normal control individuals, and the area under curve was 0.83. In particular, higher expression was associated with luminal breast cancer subtype as well as respective cell lines. S100A11 siRNA effectively inhibited the proliferation, invasion, and migration abilities of MCF-7 and T-47D cells. Knockdown of S100A11 caused cell cycle G1 arrest and induced apoptosis. Silencing of S100A11 decreased the mRNA and protein expression levels of cyclin D1 and NF-κB p50 whereas increased the expression level of E-cadherin in MCF-7 and T-47D cells.
Conclusion: These results suggest that S100A11 is upregulated in breast cancer and promoted cell proliferation, invasion and migration in MCF-7 and T-47D cells through the upregulation of NF-κB p50 and cyclin D1. Thus, S100A11 may be a potential diagnostic marker for luminal breast cancer subtype and also a therapeutic target for breast cancer.
Citation Format: Kwong A, Wang J, Chen J, Siu MT, Chuek I, Shin V. S100A11 is a diagnostic marker and promotes cancer progression for luminal breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-24.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - J Wang
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - J Chen
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - MT Siu
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - I Chuek
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| | - V Shin
- The University of Hong Kong, Pokfulam, Hong Kong; The Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
| |
Collapse
|
6
|
Kwong A, Shin VY, Ma ES, Chan CT, Ford JM, Kurian AW, Tai E. Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations. Hong Kong Med J 2018; 24 Suppl 3:4-6. [PMID: 29937436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023] Open
Affiliation(s)
- A Kwong
- Department of Surgery, The University of Hong Kong
| | - V Y Shin
- Department of Surgery, The University of Hong Kong
| | - E Sk Ma
- Department of Surgery, The University of Hong Kong
| | - C Tl Chan
- Department of Surgery, The University of Hong Kong
| | - J M Ford
- Department of Surgery, The University of Hong Kong
| | - A W Kurian
- Department of Surgery, The University of Hong Kong
| | - E Tai
- Department of Surgery, The University of Hong Kong
| |
Collapse
|
7
|
Kwong A, Shin V, Au CH, Chan TL, Ma E. Identification of germline mutation using 30-gene sequencing and clinical characteristic of Chinese with hereditary breast cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Kwong A, Siu MT, Cheuk I, Ho JC, Chen J, Shin VY. Abstract P1-05-04: A novel mechanism of epithelial-mesenchymal transition in breast cancer metastasis: Involvement of prostanoid receptor. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer is associated with higher metastatic rate and poor prognosis than other subtypes of breast cancer due to lack of targeted therapy. Epithelial-mesenchymal transition (EMT) is linked with metastasis with phenotypic conversion of epithelial cells. However, the regulation of EMT in breast cancer metastasis remains largely unstudied. Recent attention has focused on targeting the downstream of COX-2 pathway, understanding the role of prostanoid receptors in breast cancer metastasis may help the development of effective therapeutic interventions for patients with metastasis.
Methods: A stable EP2-expression cell line (MB-231-EP2) was used to study tumorigenesis and distant metastasis in human breast cancer metastatic model. Localization of EP2 and EMT markers were examined by immunostaining and immunofluorescence. Profiles of drug transporters genes were compared between siEP2 and siControl cells. Functional role of EP2 on cell proliferation, invasion and apoptosis were assessed. Alteration of EMT markers were examined by real-time PCR and Western blot analysis.
Results: Expression of EP2 receptor were higher in human primary tumors than non-tumor tissues. EP2 receptor was predominantly expressed in metastatic tumors than primary tumors in human breast cancer metastatic mice model. The metastatic tumors showed a higher Ki67 (cell proliferation) and CD31 (angiogenesis) than primary tumors in the xenograft tissues. Larger tumors and poor survival were seen in MD-231-EP2 bearing mice when compared with control. Silencing of EP2 by siRNA markedly reduced cell proliferation and invasion, but increased apoptosis and expression of solute carrier family 19 member A3 (SLC19A3) gene. Interestingly, SLC19A3 had a lower expression in primary tumors and was inversely correlated with EP2 expression. Ectopic expression of SLC19A3 suppressed cell proliferation and invasion through the restoration of E-cadherin and other EMT markers (Twist, Zeb1 and Snai2). Immunofluorescence staining showed that the localization of Twist and E-cadherin were altered in siEP2 cells.
Conclusion: Our results showed that EP2 promoted EMT and breast cancer metastasis through the downregulation of SLC19A3 expression. Taken together, targeting EP2/SLC19A3 signaling pathway maybe a potential treatment for metastasis and adjuvant chemotherapy to reduce the metastatic risk.
Citation Format: Kwong A, Siu MT, Cheuk I, Ho JC, Chen J, Shin VY. A novel mechanism of epithelial-mesenchymal transition in breast cancer metastasis: Involvement of prostanoid receptor. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-05-04.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - MT Siu
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - I Cheuk
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - JC Ho
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - J Chen
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - VY Shin
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| |
Collapse
|
9
|
Kwong A, Shin VY, Au CH, Law FB, Ho DN, Ip BK, Wong AT, Lau SS, To RM, Choy G, Ford JM, Ma ES, Chan TL. Abstract P2-09-20: Evaluation on the mutation screening by next-generation sequencing in hereditary breast and ovarian cancer: Implementation of recurrent mutation panel. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hereditary disposition accounts for 10-15% in breast cancers and 20-25% in ovarian cancers, in which 5-10% of women have genomic alteration in breast cancer predisposition genes, BRCA1 and BRCA2, while the rest are likely due to less penetrant genes. In specific ethnicities such as Ashkenazi Jewish, three founder mutations have been identified which covers 95 % of all the BRCA mutations identified in this race. These genes are screened prior to the gold standard Sanger Sequencing in order to reduce cost. Sanger Sequencing, however, still has the limitation on the necessity of laborious processing and results interpretation. Moreover, it limits the number of genes that can be analyzed in one setting. With the use of next-generation sequencing (NGS), identification of hereditary breast and ovarian cancer (HBOC) syndrome associated genes, other than BRCA, can be sequenced at the same time but yet a faster turnover time. This allows more timely targeted risk-reducing strategies and interventions to be implemented for mutation positive carriers and their family members.
Methods: In this study cohort, 948 high-risk breast/ovarian patients who met the HBOC selection criteria were recruited for mutation screening by our NGS pipeline. With the inclusion of 90 Sanger-validated known mutation cases, the performance of the NGS pipeline were proven to be comparable to Sanger sequencing. PTEN and TP53, other than BRCA1 and BRCA2, a 4 gene sequencing panel were included in the mutation screening for high-risk patients.
Results: The prevalence of BRCA1/BRCA2 germline mutations was 7.28% in our Chinese cohort and 47.8% of the mutation were recurrent mutations. Based on this finding, we further adopted a new workflow by screening the recurrent mutations including founder mutations from Chinese cohort prior to NGS for those who tested negative. In a testing cohort of 343 cases, the recurrent mutation pick-up rate was 3.5%, this implicated a more cost-effective method for mutation screening in the clinical setting. Moreover, the frequencies of PTEN and TP53 were 0.21% and 0.53% respectively in our population with breast and ovarian cases.
Conclusion: Taken together, our data demonstrated a strategic upfront screening for recurrent mutations in Chinese population which is highly applicable in most of the diagnostic laboratories. Multi-gene sequencing using the NGS technology will be the upcoming strategies for mutation screening for HBOC patients.
Citation Format: Kwong A, Shin VY, Au CH, Law FB, Ho DN, Ip BK, Wong AT, Lau SS, To RM, Choy G, Ford JM, Ma ES, Chan TL. Evaluation on the mutation screening by next-generation sequencing in hereditary breast and ovarian cancer: Implementation of recurrent mutation panel. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-20.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - VY Shin
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - CH Au
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - FB Law
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - DN Ho
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - BK Ip
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - AT Wong
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - SS Lau
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - RM To
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - G Choy
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - JM Ford
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - ES Ma
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| | - TL Chan
- The University of Hong Kong, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; Stanford University School of Medicine
| |
Collapse
|
10
|
Shin VY, Siu JM, Cheuk I, Ng EKO, Kwong A. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 2015; 112:1751-9. [PMID: 25906045 PMCID: PMC4647231 DOI: 10.1038/bjc.2015.143] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Revised: 03/10/2015] [Accepted: 03/16/2015] [Indexed: 02/06/2023] Open
Abstract
Background: Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer in women globally. This subtype often has early and high recurrence rates resulting in poor survival, partially due to lack of targeted therapies. Therefore, there is an urgent need to identify TNBC-specific biomarkers for early diagnosis and treatment monitoring, and to develop more effective targeted therapy. Methods: By using miRCURY LNA array platform, we compared the differential miRNA expressions in plasma of patient with TNBC (n=5) and non-TNBC (n=5), as well as healthy controls (n=5). Potential miRNAs were then validated in a large cohort of patients by real-time PCR. Results: Ten putative miRNAs from the microarray data that differentially expressed between non-TNBC and healthy controls were identified. In the screening phase (n=90), we selected five miRNAs (miR-92a-3p, miR-342-3p, miR-16, miR-21 and miR-199a-5p) that could discriminate TNBC from non-TNBC for further validation. Results showed that miR-16, miR-21 and miR-199a-5p were underexpressed in TNBC when compared with non-TNBC, and were further validated in a large cohort (n=252). In addition, post-operative plasma levels of miR-16, miR-21 and miR-199a-5p were significantly restored when compared with pre-operative plasma of TNBC. Plasma miR-199a-5p expression in TNBC had significant difference when compared with non-TNBC and healthy controls, the receiver-operator characteristics curve analysis revealed the highest area under curve (AUC=0.8838) among all. The expression levels were associated with TNM stage and tumour subtypes. Conclusions: Our data suggest that miR-199a-5p could be a TNBC-specific marker with diagnostic value and provide insights into targeted therapy in the treatment of TNBC.
Collapse
Affiliation(s)
- V Y Shin
- Department of Surgery, the University of Hong Kong, Hong Kong SAR, China
| | - J M Siu
- Department of Surgery, the University of Hong Kong, Hong Kong SAR, China
| | - I Cheuk
- Department of Surgery, the University of Hong Kong, Hong Kong SAR, China
| | - E K O Ng
- Department of Surgery, the University of Hong Kong, Hong Kong SAR, China
| | - A Kwong
- 1] Department of Surgery, the University of Hong Kong, Hong Kong SAR, China [2] The Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong SAR, China
| |
Collapse
|
11
|
Kwong A, Chen J, Shin V, Law F, Chan T, Ford J. P140 Identification of BRCA1/2 germline mutations by integrated approach. Breast 2015. [DOI: 10.1016/s0960-9776(15)70182-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Kwong A, Au CH, Law FB, Ho DN, Ip BK, Wong AT, Shin VY, Chan TL, Ma ES. Abstract P2-07-03: High-throughput germline mutation screening for hereditary breast cancer in southern Chinese patients by massively parallel DNA sequencing. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Breast cancer is the most common malignancy and 3rd leading cause of deaths among the female population in Hong Kong. Since the establishment of The Hong Kong Hereditary Breast Cancer Family Registry in 2007, 1344 patients with breast and/or ovarian cancer who met the selection criteria were recruited for genetic testing in Hong Kong. Since 2011 we started to employ next-generation DNA sequencing (NGS) to expedite the analysis workflow and expand the panel of genes for sequencing.
Aim: To evaluate the workflow of NGS in mutation screening of BRCA1, BRCA2, TP53 and PTEN genes, and compared with the sequence data obtained by Sanger sequencing.
Methods: We sequenced BRCA1, BRCA2, TP53 and PTEN genes in peripheral blood samples of 410 patients, 53 positive controls and 107 healthy local individuals using 454 GS Junior System. Generation of barcoded amplicon libraries was streamlined by microfluidic PCR using Fluidigm Access Array System. Sequencing data were analyzed by an in-house developed fully automatic bioinformatics pipeline, which mainly consists of GS Amplicon Variant Analyzer, SAMtools and Ensembl Variant Effect Predictor. All putative mutations identified were validated by Sanger sequencing. Furthermore, the frequency of BRCA1, BRCA2 and PTEN missense variants of unknown significance (VUS) identified in the cohort were compared among 107 healthy local individuals and 1000 Genomes project samples. The VUS were also subjected to a panel of in silico prediction methods including PolyPhen and SIFT.
Results: Among 410 patients, there were 7 in BRCA1, 6 in BRCA2 and 1 in TP53 mutations found, including 1 novel recurrent BRCA2 (c.7007G>T) and 1 novel founder BRCA2 (c.5164_5165delAG) mutations. Based on multiple criteria, 12 in BRCA1, 12 in BRCA2 and 1 in PTEN VUS could be prioritized for further investigation. The bioinformatics pipeline was extensively evaluated with Sanger-validated controls. The evaluation determined minimum sequencing coverage needed in this sequencing platform for accurate analysis. The pipeline accuracy was demonstrated by successful detecting mutations from 53 positive controls, including single nucleotide variants, insertions and deletions in different sequence context.
Conclusion: BRCA1, BRCA2, TP53 and PTEN mutation screening of 410 patients were expedited by high-throughput DNA sequencing. This method could detect 14 positive cases, including recurrent mutations, in a shorter period of time when compared with Sanger full gene sequencing. High-risk patients who are negative for the gene panel may need further investigation other than screening for BRCA1/2. The in-house developed bioinformatics pipeline was validated to detect various types of mutations and potentially become a conventional platform for genetic screening.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-07-03.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - CH Au
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - FB Law
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - DN Ho
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - BK Ip
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - AT Wong
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - VY Shin
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - TL Chan
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| | - ES Ma
- The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry
| |
Collapse
|
13
|
Ng EKO, Leung C, Shin VY, Chan A, Wong CLPL, Ma ESK, Jin HC, Chu KM, Kwong A. Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Previously, we have examined the methylation status of SLC19A3 (solute carrier family 19, member 3) promoter and found that SLC19A3 was epigenetically down-regulated in gastric cancer. Here, we aim to develop a new biomarker for cancer diagnosis using methylated SLC19A3 DNA in plasma.
Methods: SLC19A3 gene expression was examined by RT-qPCR. Methylation status of SLC19A3 promoter was evaluated by methylation-specific qPCR. A robust and simple methylation-sensitive restriction enzyme digestion and real-time quantitative PCR assay was developed to quantify SLC19A3 DNA methylation in plasma. Results: Expression of SLC19A3 was significantly down-regulated in 80% (12/15) of breast tumors (P < 0.005). Breast tumors had significant increase in methylation percentage when compared to adjacent non-tumor tissues (P < 0.05). A total of 155 independent plasma samples from participants including 60 breast cancer, 45 gastric cancer patients and 60 healthy subjects were analyzed. Plasma methylated SLC19A3 DNA yielded a ROC curve area of 77%, sensitivity of 82% and specificity of 60% in discriminating breast cancer from control subjects. This marker yielded a ROC curve area of 87%, sensitivity of 90.0% and specificity of 62% in discriminating gastric cancer from control subjects. Elevated level in plasma has been detected not only in advanced stages but also early stages of tumors. Intriguingly, of all DCIS cases from breast cancer patients this plasma marker generated a ROC value of 92%, sensitivity of 100% and specificity of 78% in discriminating DCIS cases from controls. Conclusions: These results suggested that aberrant SLC19A3 promoter hypermethylation in plasma may be a novel biomarker for early breast cancer diagnosis.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-01-02.
Collapse
Affiliation(s)
- EKO Ng
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - C Leung
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - VY Shin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - A Chan
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - CLPL Wong
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - ESK Ma
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - HC Jin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - KM Chu
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| | - A. Kwong
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanatorium & Hospital, Hong Kong; Sir Runrun Shaw Hospital, Zhejiang University, China
| |
Collapse
|
14
|
Liu X, Wang X, Zhang J, Lam EKY, Shin VY, Cheng ASL, Yu J, Chan FKL, Sung JJY, Jin HC. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2009; 29:442-50. [PMID: 19881551 DOI: 10.1038/onc.2009.332] [Citation(s) in RCA: 134] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P<0.01, n=22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P=0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect.
Collapse
Affiliation(s)
- X Liu
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ng EKO, Chong WWS, Jin H, Lam EKY, Shin VY, Yu J, Poon TCW, Ng SSM, Sung JJY. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009. [PMID: 19201770 DOI: 10.1136/gut.2008.167817;] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC). METHODS This study was divided into three phases: (1) marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of five patients with CRC, along with plasma from five healthy individuals as controls; (2) marker selection and validation by real-time quantitative RT-PCR on a small set of plasma; and (3) independent validation on a large set of plasma from 90 patients with CRC, 20 patients with gastric cancer, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. RESULTS Of the panel of 95 miRNAs analysed, five were upregulated both in plasma and tissue samples. All the five miRNAs were validated on the plasma of 25 patients with CRC and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in the patients with CRC (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 patients with CRC (p<0.05). Further validation with an independent set of plasma samples (n = 180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cut-off of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. CONCLUSION MiR-92 is significantly elevated in plasma of patients with CRC and can be a potential non-invasive molecular marker for CRC screening.
Collapse
Affiliation(s)
- E K O Ng
- Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ng EKO, Chong WWS, Jin H, Lam EKY, Shin VY, Yu J, Poon TCW, Ng SSM, Sung JJY. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58:1375-81. [PMID: 19201770 DOI: 10.1136/gut.2008.167817] [Citation(s) in RCA: 938] [Impact Index Per Article: 62.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVE MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC). METHODS This study was divided into three phases: (1) marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of five patients with CRC, along with plasma from five healthy individuals as controls; (2) marker selection and validation by real-time quantitative RT-PCR on a small set of plasma; and (3) independent validation on a large set of plasma from 90 patients with CRC, 20 patients with gastric cancer, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. RESULTS Of the panel of 95 miRNAs analysed, five were upregulated both in plasma and tissue samples. All the five miRNAs were validated on the plasma of 25 patients with CRC and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in the patients with CRC (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 patients with CRC (p<0.05). Further validation with an independent set of plasma samples (n = 180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cut-off of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. CONCLUSION MiR-92 is significantly elevated in plasma of patients with CRC and can be a potential non-invasive molecular marker for CRC screening.
Collapse
Affiliation(s)
- E K O Ng
- Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ye YN, Wu WKK, Shin VY, Bruce IC, Wong BCY, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005; 26:827-34. [PMID: 15637091 DOI: 10.1093/carcin/bgi012] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Previous studies indicate that the arachidonic acid-metabolizing enzymes COX-2 and 5-LOX are overexpressed during the process of colonic adenoma formation promoted by cigarette smoke. The aims of the present study were to investigate whether there exists a relationship between COX-2 and 5-LOX, and whether dual inhibition of COX-2 and 5-LOX has an anticarcinogenic effect in the colonic tumorigenesis promoted by cigarette smoke. Results showed that pretreating colon cancer cells with cigarette smoke extract (CSE) promoted colon cancer growth in the nude mouse xenograft model. Inhibition of COX-2 or 5-LOX reduced the tumor size. In the group treated with COX-2-inhibitor, the PGE2 level decreased while the LTB4 level increased. In contrast, in the 5-LOX-inhibitor treated group, the LTB4 level was reduced and the PGE2 level was unchanged. However, combined treatment with both COX-2 and 5-LOX inhibitors further inhibited the tumor growth promoted by CSE over treatment with either COX-2-inhibitor or 5-LOX-inhibitor alone. This was accompanied by the downregulation of PGE2 and LTB4. In an in vitro study, we found that the action of CSE on colon cancer cells was mediated by 5-LOX DNA demethylation. In summary, these results indicate that inhibition of COX-2 may lead to a shunt of arachidonic acid metabolism towards the leukotriene pathway during colonic tumorigenesis promoted by CSE. Suppression of 5-LOX did not induce such a shunt and produced a better response. Therefore, 5-LOX inhibitor is more effective than COX-2 inhibitor, and blocker of both COX-2 and 5-LOX may present a superior anticancer profile in cigarette smokers.
Collapse
Affiliation(s)
- Y N Ye
- Department of Pharmacology, Faculty of Medicine, Zhejiang University, Hangzhou, Republic of China
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Our previous study showed that a crude extract from Angelica sinensis (ASCE), which mainly consisted of polysaccharides, significantly promoted migration and proliferation of normal gastric epithelial cells. These results strongly suggest that ASCE has a direct wound healing effect on gastric mucosa. However, there is no report concerning the effect of ASCE on gastric ulcer healing in animal models. In this study, we found that ASCE promoted ulcer healing. The area of the ulcer was reduced. This was accompanied with a significant increase in mucus synthesis when compared with the control. Angiogenesis was inhibited by the treatment of ASCE. Cell proliferation, ODC and EGFR protein expression was not affected in this process. Thus, the mechanism of how ASCE accelerates ulcer healing in addition to its effect on mucus synthesis remains to be investigated.
Collapse
Affiliation(s)
- Y N Ye
- Department of Pharmacology, L02-55, 2/F, Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, University of Hong Kong, Hong Kong, PR China
| | | | | | | | | |
Collapse
|
19
|
Abstract
BACKGROUND Previous studies have shown that intragastric administration of unfractionated heparin enhances gastric ulcer healing in rats. As the large molecule of heparin may be partially degraded in the upper gastrointestinal tract, it is likely that fragments of heparin, derived from the unfractionated parent compound, are involved in the anti-ulcer action in the stomach. Therefore, it is possible that low molecular weight heparin may have a similar ulcer healing effect. METHODS Male Sprague-Dawley rats with acetic acid-induced gastric ulcers were given a 3.0-kDa low molecular weight heparin (0.6-6.0 mg/kg) intravenously or intragastrically once daily for 4 days. Ulcer healing, mucosal histological changes, angiogenesis and gastric mucus production both in vivo and in vitro were determined. The bleeding time was measured to indicate the anticoagulation activity. RESULTS Both intravenous and intragastric low molecular weight heparin dose dependently accelerated gastric ulcer healing, which was accompanied by a significant increase in mucosal regeneration and proliferation, angiogenesis and mucus content in the stomach. The drug also stimulated the mucus production in MKN-28 cells. Drug administration by either route did not alter the bleeding time in rats. CONCLUSIONS A 3.0-kDa low molecular weight heparin possesses an ulcer healing effect similar to that of unfractionated heparin in the stomach of the rat. This smaller molecular drug is superior to the unfractionated form, does not affect the coagulation activity and may show better absorption in the gastrointestinal tract.
Collapse
Affiliation(s)
- Y Li
- Department of Pharmacology, Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | | | | | | | | |
Collapse
|
20
|
Abstract
Heme oxygenase (HO) is the rate-limiting enzyme in the catabolism of heme, followed by production of biliverdin, free iron and carbon monoxide (CO). There are three isoforms of HO: HO-1 is highly inducible, whereas HO-2 and HO-3 are constitutively expressed. In addition to heme, a variety of nonheme compounds, including heavy metals, cytokines, endotoxins and heat shock stress are strong inducers of HO-1 expression. Many studies indicated that induction of HO-1 is associated with a protective response due to the removal of free heme, which is shown to be toxic. However, recent studies demonstrated that the expression of HO-1 in response to different inflammatory mediators could contribute in part to the resolution of inflammation and have protective effects on brain, liver, kidney and lung against injuries. These beneficial effects seem to be due to the production of bile pigment biliverdin and bilirubin that is a potent antioxidant, as well as the release of iron and CO. However, there are few studies concerning the relationship between HO-1 and inflammation as well as injury in the gut. Interestingly, a preliminary study implicated that induction of HO-1 expression in a colonic damage model induced by trinitrobenzene sulfonic acid played a critical protective role, indicating that activation of HO-1 could act as a natural defensive mechanism to alleviate inflammation and tissue injury in the gastrointestinal tract.
Collapse
Affiliation(s)
- X Guo
- Department of Pharmacology, Faculty of Medicine, The University of Hong Kong, SAR, PR China
| | | | | |
Collapse
|
21
|
Wong BC, Wang WP, So WH, Shin VY, Wong WM, Fung FM, Liu ES, Hiu WM, Lam SK, Cho CH. Epidermal growth factor and its receptor in chronic active gastritis and gastroduodenal ulcer before and after Helicobacter pylori eradication. Aliment Pharmacol Ther 2001; 15:1459-65. [PMID: 11552919 DOI: 10.1046/j.1365-2036.2001.01051.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Helicobacteria pylori infection of gastroduodenal mucosa is strongly associated with gastritis and peptic ulcer disease. The aims of the present study were to compare the gastroduodenal mucosal levels of epidermal growth factor (EGF) and its receptor (EGFR) among H. pylori-negative controls and H. pylori infected patients with chronic active gastritis or gastroduodenal ulcer before and after H. pylori eradication. METHODS The protein levels of EGF in mucosal tissues and saliva were determined by a solid-phase enzyme-linked immunosorbent assay (ELISA). Repeat transcription-polymerase chain reaction and the following polymerase chain reaction ELISA were employed to examine the mucosal EGFR mRNA expression. RESULTS Mucosal injury and H. pylori infection increased EGF protein levels and EGFR mRNA expression in the antral mucosa. The concentration of EGF in saliva was not affected by mucosal damage or H. pylori infection. Successful H. pylori eradication normalized the EGFR mRNA back to its basal level 6 weeks after treatment. However, after unsuccessful eradication their high levels in the antrum persisted. All patients experienced ulcer healing after drug treatment, regardless of H. pylori eradication. CONCLUSIONS Mucosal damage increased the expression of EGF protein and EGFR mRNA in the gastric mucosa. H. pylori could induce the expression of EGFR but not the EGF in the antral mucosa. The expression of EGFR could be a contributing factor for ulcer healing in patients with H. pylori infection.
Collapse
Affiliation(s)
- B C Wong
- Department of Pharmacology, Faculty of Medicine, the University of Hong Kong, Hong Kong, SAR, P.R. China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ye YN, Liu ES, Shin VY, Koo MW, Li Y, Wei EQ, Matsui H, Cho CH. A mechanistic study of proliferation induced by Angelica sinensis in a normal gastric epithelial cell line. Biochem Pharmacol 2001; 61:1439-48. [PMID: 11331080 DOI: 10.1016/s0006-2952(01)00625-6] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
It has been reported that an extract from Angelica sinensis mainly consisting of polysaccharides (95%) prevented ethanol- or indomethacin-induced gastric mucosal damage (Cho CH et al. Planta Med 2000;66:348-51). However, it is not known whether Angelica sinensis has a direct stimulatory effect on the healing of gastric mucosal lesions. To study the hypothesis that Angelica sinensis has a direct mucosal healing effect in rats and in isolated gastric epithelial cells, we assessed the wound repair in both animals and normal cell culture (RGM-1), as well as [3H]thymidine incorporation, ornithine decarboxylase (ODC) activity, and ODC protein and c-Myc protein expression after different treatments in RGM-1 cells. We found that Angelica sinensis crude extract (ASCE) dose-dependently enhanced gastric ulcer healing in rats and promoted wound repair in RGM-1 cells. It also significantly stimulated [3H]thymidine incorporation and ODC activity in RGM-1 cells in a concentration-dependent manner. ODC and c-Myc protein expression was also increased as a result of this process. DL-alpha-difluoromethyl-ornithine repressed the [3H]thymidine incorporation and ODC activity induced by ASCE. Pretreatment with c-Myc antisense oligodeoxynucleotides blocked the stimulatory action of ASCE on [3H]thymidine incorporation and ODC protein expression. These data suggest that ASCE has a direct mucosal healing effect on gastric epithelial cells, while ODC and c-Myc are closely associated with this effect.
Collapse
Affiliation(s)
- Y N Ye
- Department of Pharmacology, The University of Zhejiang, Hangzhou, China
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998; 18:1964-71. [PMID: 9848891 DOI: 10.1161/01.atv.18.12.1964] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Vascular calcification is a frequent component of atherosclerosis, yet the pathological mechanisms that regulate its formation are poorly understood. Calcification of the vessel wall may represent a process by which cells that normally exhibit a smooth muscle phenotype differentiate into cells that exhibit an osteoblast-like phenotype. One of the determinants of cellular phenotype is extracellular matrix; thus, we undertook the current study to evaluate the influence of extracellular matrix on calcification of vascular cells in vitro. Cell lines derived from bovine aortic media were divided into 1 of 3 groups: those that did not mineralize, those that mineralized slowly, or those that mineralized rapidly. When slowly mineralizing cells were plated onto matrix produced by rapidly mineralizing cells, the time required for mineralization decreased from 33+/-3.0 days to 7.8+/-1.3 days. Matrix produced by rapidly mineralizing cells was found to contain 3 times the amount of collagen I and fibronectin but 70% less collagen IV than nonmineralizing clones. When slowly mineralizing cells were cultured on purified collagen I or fibronectin, mineralized nodule formation, calcium incorporation, von Kossa staining, and alkaline phosphatase activity increased. In contrast, culturing slowly mineralizing cells on purified collagen IV inhibited these mineralization parameters. Furthermore, blocking antibodies to alpha5 integrins significantly inhibited the fibronectin-mediated increases in alkaline phosphatase activity, indicating that integrin-based signaling may be involved. These data suggest that matrix composition can regulate development of arterial calcification and that a subpopulation of vascular cells preferentially produces positively regulating matrix components.
Collapse
Affiliation(s)
- K E Watson
- Division of Cardiology, Departments of Medicine and Physiology, UCLA School of Medicine, Los Angeles, CA, USA.
| | | | | | | |
Collapse
|
24
|
Abstract
Ankyrins are a multigene family of proteins that function as adapters between the cytoskeleton and trans-membrane proteins, such as ion channels. Previous studies have shown the linkage between ankyrin and ionic transport proteins such as Na+-K+ ATPase, voltage-dependent Na+ channels and Ca2+ channels. In the present study, we have investigated the subcellular distribution of ankyrin and its relationship to the Na+-Ca2+ exchange protein in immature and adult rabbit ventricular myocytes. Isolated single cardiomyocytes from neonatal, juvenile and adult rabbit hearts were examined by immunofluorescence labeling techniques, using antibodies against ankyrin and the Na+-Ca2+ exchanger. We found that in neonatal rabbit cardiac myocytes, ankyrin labeling was mainly present at the Z disk, whereas the Na+-Ca2+ exchanger was only present on the peripheral sarcolemma. At 2 weeks of age, ankyrin labeling was still predominantly observed at the level of the Z disks as well as in the partially developed T-tubules. In the adult cells, however, ankyrin and the Na+-Ca2+ exchanger seem to be co-localized within T-tubules and at the costamere region of the peripheral sarcolemma. Immunogold labeling studies at the higher resolution electron microscopic level using cyrosection tissues of rabbit heart at different ages confirm these findings. These results indicate that the distribution pattern of ankyrin and the Na+-Ca2+ exchanger changes with development in rabbit ventricular myocytes.
Collapse
Affiliation(s)
- F Chen
- University of California Los Angeles, School of Medicine, Los Angeles, California 90095-1760, USA
| | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Arterial calcification, common in atherosclerosis, is associated with an increased risk of clinical events such as myocardial infarction. We previously identified a subpopulation of bovine aortic medial cells, calcifying vascular cells (CVCs), that have osteoblastic characteristics and form bone mineral in vitro in the form of calcified nodules. To assess whether estrogen modulates arterial calcification as well as bone calcification, we tested CVCs for estrogen receptors and for the effect of 17 beta-estradiol on formation of calcified nodules, calcium content, alkaline phosphatase activity, and osteocalcin concentration in the culture medium. METHODS AND RESULTS Estrogen receptor immunoreactivity was identified in the cytoplasm and the perinuclear region of CVCs by immunocytochemistry. CVCs were treated with 17 beta-estradiol at concentrations of 0, 5, and 10 nmol/L. Twenty-one days of 17 beta-estradiol treatment resulted in a significantly increased number of calcified nodules, visualized by von Kossa staining, as well as increased calcium content of the cultures. Increases in alkaline phosphatase activity, a marker for early osteoblastic differentiation, and secreted osteocalcin, a marker for late osteoblastic differentiation, were enhanced in cells treated with 17 beta-estradiol compared with control cells. CONCLUSIONS These results suggest that 17 beta-estradiol promotes osteoblastic differentiation and calcification in vascular cells and that estrogen may play a regulatory role in arterial calcification.
Collapse
Affiliation(s)
- M Balica
- Department of Medicine, UCLA School of Medicine 90095-1679, USA
| | | | | | | | | |
Collapse
|
26
|
Abstract
The cardiac Na+ pump (Na+ -K+ -ATPase) provides the driving force for the Na+/Ca2+ exchanger, a determinant of intracellular Ca2+ stores. Three Na+ pump alpha-catalytic subunit isoforms are expressed in human heart, alpha1 and alpha2 are expressed in rat heart, and only alpha1 is expressed in guinea pig heart. The objective of this study was to determine whether there are isoform-specific patterns of expression in the transverse tubules (T tubules) vs. the peripheral sarcolemma. In adult rat cardiomyocytes, anti-alpha1-specific antibodies labeled the T tubules more intensely than the peripheral sarcolemma, in which labeling was patchy, the same pattern reported for distribution of the Na+/Ca2+ exchanger (J. S. Frank, G. Mottino, D. Reid, R. S. Molday, and K. D. Philipson, J. Cell Biol. 117: 337-345, 1992), whereas anti-alpha2- and anti-beta1-antibodies uniformly labeled T tubules and peripheral sarcolemma. In guinea pig cardiomyocytes, an anti-alpha-antibody against an extracellular epitope evenly labeled the peripheral sarcolemma and T tubules, and immunogold labeling demonstrated coincidence of alpha-subunits and intramembranous particles in sarcolemma. In summary, Na+ pumps are located in both peripheral sarcolemma and T tubules of cardiomyocytes expressing either multiple or single Na+ pump isoforms.
Collapse
Affiliation(s)
- A A McDonough
- Department of Physiology and Biophysics, University of Southern California School of Medicine, Los Angeles 90033, USA
| | | | | | | |
Collapse
|